@article{ref1,
title="Abuse-deterrent extended-release oxycodone and risk of opioid-related harm",
journal="Addiction",
year="2021",
author="Luciano, Sierra and Quinn, Patrick D. and Strang, John and Paljarvi, Tapio and Fazel, Seena",
volume="ePub",
number="ePub",
pages="ePub-ePub",
abstract="AIM: To establish and quantify the association between abuse-deterrent formulation (ADF) oxycodone and 1-year risk of opioid-related harm. <br><br>DESIGN: Propensity  score-matched cohort study of electronic medical records for years 2014 - 2018, with  patients followed up for 1 year after their index healthcare visit. SETTING: Over 70  million patients from 56 US healthcare organizations. PARTICIPANTS: Patients aged 18  - 64 years at index healthcare visit with any indication for an oral opioid  analgesic, with no past 12-month history of oral oxycodone use or substance use  disorder, and who were alive at the end of the 1-year follow-up (new episode of  prescription oral ADF oxycodone, n= 45,045; new episode of non-ADF oxycodone opioid  preparation, n=1,377,359). MEASUREMENTS: International Classification of Diseases  Clinical Modification diagnoses of any opioid-related disorder or non-fatal opioid  poisoning within 1 year of the index healthcare visit. Pooled odds ratios (OR) with  95% confidence intervals (95%CI). <br><br>FINDINGS: After propensity score matching, 89,802  patients with a mean age of 44 (SD:11) years (62% women, 68% white) were included. During 1-year follow-up, 1,445 diagnoses of opioid use disorder or opioid poisoning  occurred in the ADF oxycodone cohort (34.8/1,000 person-years), and 765 occurred in  the non-ADF oxycodone cohort (18.2/1,000 person-years). The odds of opioid-related  adverse outcomes were increased in the ADF oxycodone cohort compared with non-ADF  oxycodone opioid cohort, including for opioid use disorders (OR:2.02; 95%CI:1.83,  2.23) and opioid poisoning (OR:1.64 95%CI:1.35, 1.99). <br><br>CONCLUSIONS: Patients with a  new prescription of abuse-deterrent formulation oxycodone may be at increased risk  of opioid-related harm.<p /> <p>Language: en</p>",
language="en",
issn="0965-2140",
doi="10.1111/add.15392",
url="http://dx.doi.org/10.1111/add.15392"
}